{
    "symbol": "VIVE",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 18:38:04",
    "content": " This includes remarks about the corporation's cost, timing, progress and results of its clinical trials, including the initiation, progress of and results from our PURSUIT trial and whether the clinical trial will support the intended uses for treatment of stress urinary incontinence, or SUI, in the United States, fluctuation of global market economic conditions impact of COVID-19 on clinical development, regulatory review and clearances, manufacturing, system placements and utilization projections, expectations, plans, beliefs and prospects. Our goal is to continue to increase awareness of and build upon our body of clinical evidence that supports the safety and efficacy of the Viveve treatment as we advance our program towards a potential new SUI indication in the U.S. During the second quarter of this year, the focus of our entire organization was to continue to advance our SUI clinical development program and to successfully execute our core initiatives. Through the remainder of 2022, we intend to successfully complete our landmark PURSUIT trial, expand our installed base in the United States and Asia Pacific regions with core medical specialties, support our existing and new customers to drive increased treatment tip utilization and sales and to continue the financial efficiencies we have achieved over the last two years."
}